Biomarkers /

SMARCE1

Back to Biomarkers List

Overview

Location [1]
17q21.2
Protein [2]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1
Synonyms [1]
CSS5, BAF57

SMARCE1 is altered in 0.62% of all cancers with esophageal adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, melanoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].

SMARCE1 GENIE Cases - Top Diseases

The most common alterations in SMARCE1 are SMARCE1 Amplification (0.40%), SMARCE1 A308T (0.03%), SMARCE1 D375N (0.02%), SMARCE1 E330K (0.02%), and SMARCE1 Fusion (0.02%) [3].

SMARCE1 GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.